secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0001213900-22-046326
Event type: leadership
Sentiment:  negative
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Director Robert Dickey IV resigns over disagreement with management on financial disclosures
--------------------------------------------------------------------------------

- Robert Dickey IV resigned from Emmaus board and audit committee effective Aug 4, 2022, citing disagreement with management.
- Management provided data showing improved monthly sales since Q4 2021/Q1 2022 and projections for growth and debt paydown.
- Dickey disagreed with the timeliness and adequacy of the information provided by management.
- The resignation letter is filed as Exhibit 99.1 to the 8-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390022046326/0001213900-22-046326-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390022046326/ea164075-8k_emmaus.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-046326

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer